Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy

Songlin Liu, Haiyang Wang, Xinzhe Shao, Haonan Chen, Shushu Chao, Yanyan Zhang, Zhaoju Gao, Qingqiang Yao, Pingping ZhangJournal of Nanobiotechnology 2023 · DOI

TL;DR

This review explores how nanotechnology is revolutionizing PD-1 blockade therapy for cancer. By encapsulating PD-1 inhibitors and other therapeutic agents within nanomaterials, researchers are developing smarter delivery systems to improve efficacy, reduce side effects, and overcome resistance in cancer immunotherapy.

What Problem Does This Paper Address?

Cancer immunotherapy, particularly immune checkpoint blockade targeting PD-1, has shown remarkable success in treating various cancers. However, its clinical application is hampered by two major challenges: low patient responsiveness and significant immune-related adverse effects. Many tumors don't respond to PD-1 blockade alone, and when combined with other therapies, side effects can be severe. This paper addresses the need for improved PD-1 blockade strategies that can enhance therapeutic outcomes while minimizing toxicity.

Methods

This paper is a comprehensive review, not an experimental study. It synthesizes existing research on the application of nanomaterials for delivering PD-1 inhibitors. The authors categorize and discuss various nanomaterial-based delivery systems, including:

  • Single-drug delivery: Nanocarriers designed to deliver PD-1 inhibitors alone, focusing on targeted delivery and controlled release.
  • Combination therapy: Nanomaterials engineered to co-deliver PD-1 inhibitors with:
  • Other immunomodulators (e.g., anti-CTLA-4 antibodies, OX40 antibodies)
    • Chemotherapeutic drugs (e.g., paclitaxel, cisplatin)
    • Photothermal therapeutic agents
  • Intelligent/Responsive Nanocarriers: Nanomaterials designed to release their payload in response to specific tumor microenvironment cues (e.g., pH, ROS, MMP-2) or external stimuli (e.g., near-infrared light).
  • Targeted Delivery: Nanocarriers modified with ligands or cell membranes for active targeting to tumor cells or immune cells within the tumor microenvironment.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Nanomaterials are key to overcoming PD-1 blockade limitations: Their unique properties (small size, tunable surface, controlled release) make them ideal for enhancing PD-1 therapy.
  • Combination is crucial: Single-agent PD-1 blockade often falls short. Nanocarriers enable synergistic combinations of PD-1 inhibitors with other therapies, leading to more potent anti-tumor effects.
  • Targeting the tumor microenvironment (TME) is vital: Nanocarriers can be designed to specifically target immune cells within the TME (like TAMs, NKs, Tregs, DCs) or tumor cells themselves, improving drug delivery and reducing off-target effects.
  • "Smart" nanocarriers offer precision: Responsive nanomaterials that release drugs based on tumor-specific conditions (pH, enzymes) or external triggers (light) allow for more controlled and localized therapy.
  • Beyond antibodies: While antibodies are common PD-1 inhibitors, the review highlights the development of non-antibody inhibitors (peptides, siRNAs) delivered via nanocarriers, potentially offering advantages in cost and delivery.

Key Results

As this is a review, specific quantitative results are drawn from the cited studies. The paper highlights numerous examples where nanocarrier-based PD-1 therapies have demonstrated:

  • Improved tumor growth inhibition: Studies show significantly reduced tumor volumes and weights compared to free drug administration. For instance, one study reported a 53.24% tumor growth inhibition with anti-PD-1 NPs compared to 35.42% with free antibodies.
  • Enhanced survival rates: Combination therapies delivered via nanocarriers have shown prolonged survival in preclinical models.
  • Reduced systemic toxicity: Targeted delivery and controlled release by nanocarriers minimize drug exposure to healthy tissues, leading to fewer adverse effects.
  • Overcoming resistance: Combinations delivered by nanocarriers can address mechanisms of resistance, such as a suppressive TME or acquired drug resistance.

Limitations and Future Work

The authors acknowledge several limitations and suggest future directions:

  • Safety Evaluation: While nanocarriers aim to reduce toxicity, comprehensive safety studies are still needed for many systems before clinical translation.
  • Higher-Order Combinations: There's a need for more research into complex combinations involving PD-1 inhibitors with multiple other agents to tackle the multifaceted nature of cancer.
  • Manufacturing and Scalability: The complexity of preparing some nanocarriers poses challenges for large-scale production and clinical application.
  • Understanding Tumor Metabolism: Further exploration of how tumor metabolic therapies can synergize with PD-1 blockade is a promising avenue.
  • Local Delivery: The potential of nanocarriers in local delivery systems (e.g., electrospinning for implantable agents) to suppress tumor recurrence is an area for further development.
  • Comprehensive Data: While progress has been made, more data on the therapeutic effects of these nanodrugs across a wider range of tumors is needed.

Summary updated

Abstract

In recent years, cancer immunotherapy has emerged as an exciting cancer treatment. Immune checkpoint blockade brings new opportunities for more researchers and clinicians. Programmed cell death receptor-1 (PD-1) is a widely studied immune checkpoint, and PD-1 blockade therapy has shown promising results in a variety of tumors, including melanoma, non-small cell lung cancer and renal cell carcinoma, which greatly improves patient overall survival and becomes a promising tool for the eradication of metastatic or inoperable tumors. However, low responsiveness and immune-related adverse effects currently limit its clinical application. Overcoming these difficulties is a major challenge to improve PD-1 blockade therapies. Nanomaterials have unique properties that enable targeted drug delivery, combination therapy through multidrug co-delivery strategies, and controlled drug release through sensitive bonds construction. In recent years, combining nanomaterials with PD-1 blockade therapy to construct novel single-drug-based or combination therapy-based nano-delivery systems has become an effective mean to address the limitations of PD-1 blockade therapy. In this study, the application of nanomaterial carriers in individual delivery of PD-1 inhibitors, combined delivery of PD-1 inhibitors and other immunomodulators, chemotherapeutic drugs, photothermal reagents were reviewed, which provides effective references for designing new PD-1 blockade therapeutic strategies.
BibTeX
@article{liu2023advances,
  author = {Songlin Liu and Haiyang Wang and Xinzhe Shao and Haonan Chen and Shushu Chao and Yanyan Zhang and Zhaoju Gao and Qingqiang Yao and Pingping Zhang},
  title = {{Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy}},
  journal = {Journal of Nanobiotechnology},
  year = {2023},
  doi = {10.1186/s12951-023-01966-4},
}
Figure